Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.76 EUR | +2.04% | +8.77% | +1.81% |
05-14 | Nanobiotix to Proceed to Phase 2 Trial of Lung Cancer Treatment | MT |
04-25 | Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.81% | 337M | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- NANO Stock
- News Nanobiotix
- Top Premarket Gainers